PMC:7534795 / 19519-20195 JSON TXT 9 Projects

Annnotations TAB TSV DIC JSON TextAE

Id	Subject	Object	Predicate	Lexical cue
T116	0-96	Sentence	denotes	• Tocilizumab for IL-6 cytokine release syndrome • Multicenter Randomized controlled trial (RCT)
T117	97-125	Sentence	denotes	• Severe COVID-19 infections
T118	126-146	Sentence	denotes	• 18–85 years of age
T119	147-168	Sentence	denotes	• Elevated serum IL-6
T120	169-209	Sentence	denotes	• N = 94 standard therapy + tocilizumab
T121	210-270	Sentence	denotes	• N = 94 standard therapy • 4–8 mg/kg tocilizumab i.v. once
T122	271-402	Sentence	denotes	• Additional dose if fever persists in 24 h after first dose • First phase showed normalization of fever within 24 h of tocilizumab
T123	403-508	Sentence	denotes	• Improved respiratory function, oxygenation, and pulmonary lesions • Phase 4 study completed in May 2020
T124	509-526	Sentence	denotes	• Results pending
T125	527-676	Sentence	denotes	• Tocilizumab may be a promising investigative therapy to reduce cytokine release syndrome and associated multi-organ damage (ChiCTR2000029765, 2020)